KPV
Anti-Inflammatory Research Peptide
Size: 10mg
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-MSH, studied for anti-inflammatory signaling in laboratory research.
KPV (Lysine-Proline-Valine)
C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH)
Retains the anti-inflammatory core of α-MSH
Studied for modulation of inflammatory signaling pathways
Investigated in gut and skin research models
Small, stable sequence frequently studied alongside repair peptides
Research Use Notes
Supplied as lyophilized powder
Requires reconstitution before use
Research Water required for mixing (sold separately)
Swirl gently, never shake
Storage
Store lyophilized vial frozen for long-term holding
Keep reconstituted solution at 2 to 8°C
Protect from light and heat
Handling
Maintain sterile technique throughout reconstitution
For laboratory research use only
Avoid repeated freeze-thaw cycles to preserve integrity
Certificate of Analysis
Independently 8x Tested by Kovera Labs and/or ILS Labs
(Click here to learn about 8x testing)
All certificates are issued by independent ISO-accredited laboratories. Lot-specific documents are made available to qualified research professionals on request.
Frequently Bought Together
Commonly paired to support consistent, reliable experimentation.
BPC-157
$60.00Tissue Repair Peptide
LL-37
$70.00Antimicrobial Research Peptide
Thymosin Alpha-1
$70.00Immune Support Peptide
Compound Information
Technical specifications
What Is KPV?
α-MSH (11-13) · Lys-Pro-Val
- Type
- Tripeptide (α-MSH fragment)
- Molecular Weight
- 342.4 g/mol
- Amino Acids
- 3
Stability Information
-20°C
24+ months
2-8°C
~30 days
Sources & References
Peer-reviewed research
Products are intended solely for laboratory and scientific research purposes. Not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of disease.
All the research compounds you need, with the confidence that every batch is 8× tested before it ships.
Subscribe to our Newsletter
Subscribe to our newsletter to get daily insights, news, updates.